Adult: Monotherapy or in combination w/ other antiparkinsonian drugs for all stages of idiopathic & postencephalitic Parkinson's disease. Hyperprolactinaemia in men. Adult & ped 7-17 yr: Prolactinomas: Conservative treatment of prolactin-secreting pituitary micro- or macro-adenomas; reduce tumour size & facilitate removal prior to surgery; after surgery if prolactin level is still elevated. Adjunct in acromegaly or alternative to surgery or RT.
Adult Parkinson's disease Monotherapy or combined therapy: 10-40 mg daily.Starting dose: 1.25 mg (½ tab) daily preferably in the evening. Gradually increase dose by 1.25 mg daily each wk in 2-3 divided doses. May further increase by 2.5 mg daily each wk if therapeutic response is not reached w/in 6-8 wk. Prolactinomas 1.25 mg (½ tab) bid or tid, gradually increased to several tab daily. Acromegaly Initially 1.25 mg (½ tab) bid or tid, gradually increasing to 10-20 mg daily. Hyperprolactinaemia in men 1.25 mg (½ tab) bid or tid, gradually increased to 5-10 mg daily. Paed (7-17 yr) Prolactinomas 1.25 mg (½ tab) bid or tid, gradually increased to several tab daily. Max daily dose: 20 mg in adolescent 13-17 yr, 5 mg in childn 7-12 yr. Acromegaly Initially 1.25 mg (½ tab) bid or tid, gradually increased to several tab daily. Max daily dose: 20 mg in adolescent 13-17 yr, 10 mg in childn 7-12 yr.
Not to be used postpartum or in the puerperium in women w/ HTN, CAD, or symptoms or history of serious psychiatric disorders. Patients w/ hyperprolactinaemia (possible pituitary tumour). Carefully monitor BP, especially during 1st few days in postpartum women. Monitor signs of progressive fibrotic disorders eg, retroperitoneal fibrosis in patients on long-term, high dose therapy. Hypotensive reactions; may affect ability to drive or operate machinery. May result in ovulation; use contraceptive measures in patients not wishing to conceive; avoid oral contraceptives. Not to be used during pregnancy & lactation.
Sign Out
